Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
Sign Up to like & getrecommendations! Published in 2019 at "Blood Cancer Journal"
DOI: 10.1038/s41408-019-0254-0
Abstract: Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. However, the prognostic implication of +1q has not been evaluated in the setting of standard triplet regimens.… read more here.
Keywords: gain chromosome; myeloma; bortezomib dexamethasone; multiple myeloma ... See more keywords
Pomalidomide in multiple myeloma
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2016.1274973
Abstract: The recent introduction of novel agents (thalidomide, lenalidomide, and bortezomib) has impacted favorably on the survival of multiple myeloma (MM) patients. However, prognosis is poor for those who relapse or are refractory (RR) to lenalidomide… read more here.
Keywords: multiple myeloma; pomalidomide multiple; lenalidomide bortezomib; myeloma ... See more keywords
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18432
Abstract: Patients with multiple myeloma are at increased risk of vascular thromboembolic events (VTEs). This post hoc analysis evaluated VTEs in the randomised phase 2 GRIFFIN study (ClinicalTrials.gov Identifier: NCT02874742) that investigated lenalidomide/bortezomib/dexamethasone (RVd) ± daratumumab (D). Patients… read more here.
Keywords: griffin study; rvd; lenalidomide bortezomib; rvd rvd ... See more keywords
Combination Lenalidomide/Bortezomib Treatment Synergistically Induces Calpain-Dependent Ikaros Cleavage and Apoptosis in Myeloma Cells
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Cancer Research"
DOI: 10.1158/1541-7786.mcr-19-0431
Abstract: Multiple myeloma had been successfully treated by combining lenalidomide and bortezomib with reports suggesting benefits of such a combination even in relapsed/refractory cases. Recently, it was demonstrated that Ikaros degradation by lenalidomide happens via proteasome-dependent… read more here.
Keywords: myeloma; lenalidomide bortezomib; combination; apoptosis myeloma ... See more keywords